Mohan Bala's most recent trade in Mersana Therapeutics Inc was a trade of 281,250 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 281,250 | 281,250 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 62,500 | 62,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 14,583 | 43,750 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2025 | 14,583 | 74,811 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 0.58 per share. | 15 Jan 2025 | 5,939 | 68,872 (0%) | 0% | 0.6 | 3,445 | Common Stock |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 8,750 | 63,481 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 8,750 | 17,500 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 0.66 per share. | 13 Jan 2025 | 3,253 | 60,228 (0%) | 0% | 0.7 | 2,147 | Common Stock |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 6,250 | 56,615 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 6,250 | 6,250 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.90 per share. | 25 Oct 2024 | 1,884 | 54,731 (0%) | 0% | 1.9 | 3,580 | Common Stock |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 50,000 | 64,052 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 50,000 | 0 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 2.00 per share. | 01 Oct 2024 | 8,089 | 55,963 (0%) | 0% | 2 | 16,178 | Common Stock |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 01 Oct 2024 | 5,598 | 50,365 (0%) | 0% | 2.0 | 10,972 | Common Stock |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
| Mersana Therapeutics Inc | Bala Mohan | SVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2024 | 58,333 | 58,333 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Bala Mohan | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 8,750 | 26,250 | - | - | Restricted Stock Unit | |
| Mersana Therapeutics Inc | Mohan Bala | SVP, Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2024 | 8,750 | 17,483 (0%) | 0% | 0 | Common Stock | |
| Mersana Therapeutics Inc | Bala Mohan | SVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 2.71 per share. | 13 Jan 2024 | 3,431 | 14,052 (0%) | 0% | 2.7 | 9,298 | Common Stock |